BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 15857321)

  • 1. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of escitalopram on sleep problems in depressed patients.
    Lader M; Andersen HF; Baekdal T
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E; Niemi H
    Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A; Friis Andersen H
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP; Hermes A; Huusom AK; Weiller E
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial.
    Muller JE; Wentzel I; Koen L; Niehaus DJ; Seedat S; Stein DJ
    Int Clin Psychopharmacol; 2008 Jan; 23(1):43-8. PubMed ID: 18090507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.
    Möller HJ; Langer S; Schmauss M
    Pharmacopsychiatry; 2007 Mar; 40(2):53-7. PubMed ID: 17447173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.